|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, regional, and national cancer incidence, mortality, years
of life lost, years lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global burden of disease study. JAMA Oncol.
3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karimi P, Islami F, Anandasabapathy S,
Freedman ND and Kamangar F: Gastric cancer: Descriptive
epidemiology, risk factors, screening, and prevention. Cancer
Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takahashi T, Saikawa Y and Kitagawa Y:
Gastric cancer: Current status of diagnosis and treatment. Cancers
(Basel). 5:48–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Orditura M, Galizia G, Sforza V,
Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J,
Savastano B, Mabilia A, et al: Treatment of gastric cancer. World J
Gastroenterol. 20:1635–1649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosati G, Ferrara D and Manzione L: New
perspectives in the treatment of advanced or metastatic gastric
cancer. World J Gastroenterol. 15:2689–2692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hamashima C, Shibuya D, Yamazaki H, Inoue
K, Fukao A, Saito H and Sobue T: The Japanese guidelines for
gastric cancer screening. Jpn J Clin Oncol. 38:259–267. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choi KS, Jun JK, Lee HY, Park S, Jung KW,
Han MA, Choi IJ and Park EC: Performance of gastric cancer
screening by endoscopy testing through the national cancer
screening program of Korea. Cancer Sci. 102:1559–1564. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh
KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, et al: Screening
for gastric cancer in Asia: Current evidence and practice. Lancet
Oncol. 9:279–287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ley C, Mohar A, Guarner J,
Herrera-Goepfert R, Figueroa LS, Halperin D and Parsonnet J:
Screening markers for chronic atrophic gastritis in Chiapas,
Mexico. Cancer Epidemiol Biomarkers Prev. 10:107–112.
2001.PubMed/NCBI
|
|
10
|
Katai H and Sano T: Early gastric cancer:
Concepts, diagnosis, and management. Int J Clin Oncol. 10:375–383.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tashiro A, Sano M, Kinameri K, Fujita K
and Takeuchi Y: Comparing mass screening techniques for gastric
cancer in Japan. World J Gastroenterol. 12:4873–4874.
2006.PubMed/NCBI
|
|
12
|
Tonouchi H, Mohri Y, Kobayashi M, Tanaka
K, Ohi M and Kusunoki M: Laparoscopy-assisted distal gastrectomy
with laparoscopic sentinel lymph node biopsy after endoscopic
mucosal resection for early gastric cancer. Surg Endosc.
21:1289–1293. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kusano C, Iwasaki M, Kaltenbach T, Conlin
A, Oda I and Gotoda T: Should elderly patients undergo additional
surgery after non-curative endoscopic resection for early gastric
cancer? Long-term comparative outcomes. Am J Gastroenterol.
106:1064–1069. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
ASGE Standards of Practice Committee, ;
Ben-Menachem T, Decker GA, Early DS, Evans J, Fanelli RD, Fisher
DA, Fisher L, Fukami N, Hwang JH, et al: Adverse events of upper GI
endoscopy. Gastrointest Endosc. 76:707–718. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mukoubayashi C, Yanaoka K, Ohata H, Arii
K, Tamai H, Oka M and Ichinose M: Serum Pepsinogen and Gastric
Cancer Screening. Intern Med. 46:261–266. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miki K, Ichinose M, Shimizu A, Huang SC,
Oka H, Furihata C, Matsushima T and Takahashi K: Serum pepsinogens
as a screening test of extensive chronic gastritis. Gastroenterol
Jpn. 22:133–141. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nasrollahzadeh D, Aghcheli K, Sotoudeh M,
Shakeri R, Persson EC, Islami F, Kamangar F, Abnet CC, Boffetta P,
Engstrand L, et al: Accuracy and cut-off values of pepsinogens I,
II and gastrin 17 for diagnosis of gastric fundic atrophy:
Influence of gastritis. PLoS One. 6:e269572011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miki K and Urita Y: Using serum
pepsinogens wisely in a clinical practice. J Dig Dis. 8:8–14. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang YK, Yu JC, Kang WM, Ma ZQ, Ye X,
Tian SB and Yan C: Significance of serum pepsinogens as a biomarker
for gastric cancer and atrophic gastritis screening: A systematic
review and meta-analysis. PLoS One. 10:e01420802015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou J, Ma X, Bi F and Liu M: Clinical
significance of circulating tumor cells in gastric cancer patients.
Oncotarget. 8:25713–25720. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu Y, Ling Y, Qi Q, Lan F, Zhu M, Zhang
Y, Bao Y and Zhang C: Prognostic value of circulating tumor cells
in advanced gastric cancer patients receiving chemotherapy. Mol
Clin Oncol. 6:235–242. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
De Mattos-Arruda L, Olmos D and Tabernero
J: Prognostic and predictive roles for circulating biomarkers in
gastrointestinal cancer. Future Oncol. 7:1385–1397. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shapiro B, Chakrabarty M, Cohn EM and Leon
SA: Determination of circulating DNA levels in patients with benign
or malignant gastrointestinal disease. Cancer. 51:2116–2120. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sai S, Ichikawa D, Tomita H, Ikoma D, Tani
N, Ikoma H, Kikuchi S, Fujiwara H, Ueda Y and Otsuji E:
Quantification of plasma cell-free DNA in patients with gastric
cancer. Anticancer Res. 27:2747–2751. 2007.PubMed/NCBI
|
|
26
|
Park JL, Kim HJ, Choi BY, Lee HC, Jang HR,
Song KS, Noh SM, Kim SY, Han DS and Kim YS: Quantitative analysis
of cell-free DNA in the plasma of gastric cancer patients. Oncol
Lett. 3:921–926. 2012.PubMed/NCBI
|
|
27
|
Kim K, Shin DG, Park MK, Baik SH, Kim TH,
Kim S and Lee S: Circulating cell-free DNA as a promising biomarker
in patients with gastric cancer: Diagnostic validity and
significant reduction of cfDNA after surgical resection. Ann Surg
Treat Res. 86:136–142. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qian C, Ju S, Qi J, Zhao J, Shen X, Jing
R, Yu J, Li L, Shi Y, Zhang L, et al: Alu-based cell-free DNA: A
novel biomarker for screening of gastric cancer. Oncotarget.
8:54037–54045. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kolesnikova EV, Tamkovich SN, Bryzgunova
OE, Shelestyuk PI, Permyakova VI, Vlassov VV, Tuzikov AS, Laktionov
PP and Rykova EY: Circulating DNA in the blood of gastric cancer
patients. Ann N Y Acad Sci. 1137:226–231. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Coimbra S, Catarino C, Costa E, Oliveira
H, Figueiredo A, Rocha-Pereira P and Santos-Silva A: Circulating
cell-free DNA levels in Portuguese patients with psoriasis vulgaris
according to severity and therapy. Br J Dermatol. 170:939–942.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen C, Shi C, Huang X, Zheng J, Zhu Z, Li
Q, Qiu S, Huang Z, Zhuang Z, Wu R, et al: Molecular profiles and
metastasis markers in Chinese patients with gastric carcinoma. Sci
Rep. 9:139952019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu R, Li Q, Wu F, Shi C and Chen Q:
Comprehensive analysis of CDC27 related to peritoneal metastasis by
whole exome sequencing in gastric cancer. Onco Targets Ther.
13:3335–3346. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang R, Song S, Harada K, Ghazanfari
Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, et
al: Multiplex profiling of peritoneal metastases from gastric
adenocarcinoma identified novel targets and molecular subtypes that
predict treatment response. Gut. 69:18–31. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leon SA, Shapiro B, Sklaroff DM and Yaros
MJ: Free DNA in the serum of cancer patients and the effect of
therapy. Cancer Res. 37:646–650. 1977.PubMed/NCBI
|
|
35
|
Chen K, Zhao H, Yang F, Hui B, Wang T,
Wang LT, Shi Y and Wang J: Dynamic changes of circulating tumour
DNA in surgical lung cancer patients: Protocol for a prospective
observational study. BMJ Open. 8:e0190122018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bachet JB, Bouché O, Taieb J, Dubreuil O,
Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, et
al: RAS mutation analysis in circulating tumor DNA from patients
with metastatic colorectal cancer: The AGEO RASANC prospective
multicenter study. Ann Oncol. 29:1211–1219. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cohen JD, Li L, Wang Y, Thoburn C, Afsari
B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, et al:
Detection and localization of surgically resectable cancers with a
multi-analyte blood test. Science. 359:926–930. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deng N, Goh LK, Wang H, Das K, Tao J, Tan
IB, Zhang S, Lee M, Wu J, Lim KH, et al: A comprehensive survey of
genomic alterations in gastric cancer reveals systematic patterns
of molecular exclusivity and co-occurrence among distinct
therapeutic targets. Gut. 61:673–684. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qian Z, Zhu G, Tang L, Wang M, Zhang L, Fu
J, Huang C, Fan S, Sun Y, Lv J, et al: Whole genome gene copy
number profiling of gastric cancer identifies PAK1 and KRAS gene
amplification as therapy targets. Genes Chromosomes Cancer.
53:883–894. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Park KU, Lee HE, Park DJ, Jung EJ, Song J,
Kim HH, Choe G, Kim WH and Lee HS: MYC quantitation in cell-free
plasma DNA by real-time PCR for gastric cancer diagnosis. Clin Chem
Lab Med. 47:530–536. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Park KU, Lee HE, Nam SK, Nam KH, Park DJ,
Kim HH, Kim WH and Lee HS: The quantification of HER2 and MYC gene
fragments in cell-free plasma as putative biomarkers for gastric
cancer diagnosis. Clin Chem Lab Med. 52:1033–1040. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kinugasa H, Nouso K, Tanaka T, Miyahara K,
Morimoto Y, Dohi C, Matsubara T, Okada H and Yamamoto K: Droplet
digital PCR measurement of HER2 in patients with gastric cancer. Br
J Cancer. 112:1652–1655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shoda K, Ichikawa D, Fujita Y, Masuda K,
Hiramoto H, Hamada J, Arita T, Konishi H, Komatsu S, Shiozaki A, et
al: Monitoring the HER2 copy number status in circulating tumor DNA
by droplet digital PCR in patients with gastric cancer. Gastric
Cancer. 20:126–135. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Taby R and Issa JP: Cancer epigenetics. CA
Cancer J Clin. 60:376–392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li Y, Xu H, Su S, Ye J, Chen J, Jin X, Lin
Q, Zhang D, Ye C and Chen C: Clinical validation of a highly
sensitive assay to detect EGFR mutations in plasma cell-free DNA
from patients with advanced lung adenocarcinoma. PLoS One.
12:e01833312017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Baylin SB, Herman JG, Graff JR, Vertino PM
and Issa JP: Alterations in DNA methylation: A fundamental aspect
of neoplasia. Adv Cancer Res. 72:141–196. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jones PA and Laird PW: Cancer-epigenetics
comes of age. Nat Genet. 21:163–167. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ebrahimi V, Soleimanian A, Ebrahimi T,
Azargun R, Yazdani P, Eyvazi S and Tarhriz V: Epigenetic
modifications in gastric cancer: Focus on DNA methylation. Gene.
742:1445772020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Eyvazi S, Khamaneh AM, Tarhriz V,
Bandehpour M, Hejazi MS, Sadat ATE and Sepehri B: CpG islands
methylation analysis of CDH11, EphA5, and HS3ST2 genes in gastric
adenocarcinoma patients. J Gastrointest Cancer. 51:579–583. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Donaldson J and Park BH: Circulating tumor
DNA: Measurement and clinical utility. Annu Rev Med. 69:223–234.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen X, Gole J, Gore A, He Q, Lu M, Min J,
Yuan Z, Yang X, Jiang Y, Zhang T, et al: Non-invasive early
detection of cancer four years before conventional diagnosis using
a blood test. Nat Commun. 11:34752020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jiang P, Chan KCA and Lo YMD:
Liver-derived cell-free nucleic acids in plasma: Biology and
applications in liquid biopsies. J Hepatol. 71:409–421. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liu MC, Oxnard GR, Klein EA, Swanton C,
Seiden MV, Liu MC, Oxnard GR, Klein EA, Smith D, Richards D, et al:
Sensitive and specific multi-cancer detection and localization
using methylation signatures in cell-free DNA. Ann Oncol.
31:745–759. 2020. View Article : Google Scholar
|
|
55
|
U.S. Food and Drug Administration (FDA), .
Premarket Approval (PMA) for Epi ProColon. FDA; Silver Spring, MD:
2016
|
|
56
|
Bennett KL, Karpenko M, Lin MT, Claus R,
Arab K, Dyckhoff G, Plinkert P, Herpel E, Smiraglia D and Plass C:
Frequently methylated tumor suppressor genes in head and neck
squamous cell carcinoma. Cancer Res. 68:4494–4499. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kreuziger LM, Porcher JC, Ketterling RP
and Steensma DP: An MLL-SEPT9 fusion and t(11;17)(q23;q25)
associated with de novo myelodysplastic syndrome. Leuk Res.
31:1145–1148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Shirley M: Epi proColon® for
colorectal cancer screening: A profile of its use in the USA. Mol
Diagn Ther. 24:497–503. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Church TR, Wandell M, Lofton-Day C, Mongin
SJ, Burger M, Payne SR, Castaños-Vélez E, Blumenstein BA, Rösch T,
Osborn N, et al: Prospective evaluation of methylated SEPT9 in
plasma for detection of asymptomatic colorectal cancer. Gut.
63:317–325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Nian J, Sun X, Ming S, Yan C, Ma Y, Feng
Y, Yang L, Yu M, Zhang G and Wang X: Diagnostic accuracy of
methylated SEPT9 for blood-based colorectal cancer detection: A
systematic review and meta-analysis. Clin Transl Gastroenterol.
8:e2162017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cai L, Hood S, Kallam E, Overman D, Barker
K, Rutledge D, Riojas J, Best C, Eisenberg M and Kam-Morgan L: Epi
proColon®: Use of a non-invasive SEPT9 gene methylation
blood test for colorectal cancer screening: A national laboratory
experience. J Clin Epigenet. 4:72018. View Article : Google Scholar
|
|
62
|
Sherr CJ: The pezcoller lecture: Cancer
cell cycles revisited. Cancer Res. 60:3689–3695. 2000.PubMed/NCBI
|
|
63
|
Weisenberger DJ: Characterizing DNA
methylation alterations from the cancer genome atlas. J Clin
Invest. 124:17–23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kanyama Y, Hibi K, Nakayama H, Kodera Y,
Ito K, Akiyama S and Nakao A: Detection of p16 promoter
hypermethylation in serum of gastric cancer patients. Cancer Sci.
94:418–420. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ichikawa D, Koike H, Ikoma H, Ikoma D,
Tani N, Otsuji E, Kitamura K and Yamagishi H: Detection of aberrant
methylation as a tumor marker in serum of patients with gastric
cancer. Anticancer Res. 24:2477–2481. 2004.PubMed/NCBI
|
|
66
|
Guo L, Huang C and Ji QJ: Aberrant
promoter hypermethylation of p16, survivin, and retinoblastoma in
gastric cancer. Bratisl Lek Listy. 118:164–168. 2017.PubMed/NCBI
|
|
67
|
Abbaszadegan MR, Moaven O, Sima HR,
Ghafarzadegan K, A'Rabi A, Forghani MN, Raziee HR, Mashhadinejad A,
Jafarzadeh M, Esmaili-Shandiz E and Dadkhah E: p16 promoter
hypermethylation: A useful serum marker for early detection of
gastric cancer. World J Gastroenterol. 14:2055–2060. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Chen F, Liu X, Bai J, Pei D and Zheng J:
The emerging role of RUNX3 in cancer metastasis (Review). Oncol
Rep. 35:1227–1236. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW,
Bang YJ and Kang GH: Methylation of RUNX3 in various types of human
cancers and premalignant stages of gastric carcinoma. Lab Invest.
84:479–484. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Sakakura C, Hamada T, Miyagawa K, Nishio
M, Miyashita A, Nagata H, Ida H, Yazumi S, Otsuji E, Chiba T, et
al: Quantitative analysis of tumor-derived methylated RUNX3
sequences in the serum of gastric cancer patients. Anticancer Res.
29:2619–2625. 2009.PubMed/NCBI
|
|
71
|
Lu XX, Yu JL, Ying LS, Han J, Wang S, Yu
QM, Wang XB, Fang XH and Ling ZQ: Stepwise cumulation of RUNX3
methylation mediated by Helicobacter pylori infection
contributes to gastric carcinoma progression. Cancer.
118:5507–5517. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Lin Z, Luo M, Chen X, He X, Qian Y, Lai S,
Si J and Chen S: Combined detection of plasma ZIC1, HOXD10 and
RUNX3 methylation is a promising strategy for early detection of
gastric cancer and precancerous lesions. J Cancer. 8:1038–1044.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Shi DT, Han M, Gao N, Tian W and Chen W:
Association of RASSF1A promoter methylation with gastric cancer
risk: A meta-analysis. Tumour Biol. 35:943–948. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J,
Zhu RM, Li GL, Xia XY, Wei XW, et al: Detection of RASSF1A promoter
hypermethylation in serum from gastric and colorectal
adenocarcinoma patients. World J Gastroenterol. 14:3074–3080. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Balgkouranidou I, Matthaios D,
Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis
K, Chelis L, Trypsianis G, Chatzaki E, et al: Prognostic role of
APC and RASSF1A promoter methylation status in cell free
circulating DNA of operable gastric cancer patients. Mutat Res.
778:46–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Pimson C, Ekalaksananan T, Pientong C,
Promthet S, Putthanachote N, Suwanrungruang K and Wiangnon S:
Aberrant methylation of PCDH10 and RASSF1A genes in blood samples
for non-invasive diagnosis and prognostic assessment of gastric
cancer. PeerJ. 4:e21122016. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ohki R, Nemoto J, Murasawa H, Oda E,
Inazawa J, Tanaka N and Taniguchi T: Reprimo, a new candidate
mediator of the p53-mediated cell cycle arrest at the G2 phase. J
Biol Chem. 275:22627–22630. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Ooki A, Yamashita K, Yamaguchi K, Mondal
A, Nishimiya H and Watanabe M: DNA damage-inducible gene, Reprimo
functions as a tumor-suppressor and is suppressed by promoter
methylation in gastric cancer. Mol Cancer Res. 11:1362–1374. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Bernal C, Aguayo F, Villarroel C, Vargas
M, Díaz I, Ossandon FJ, Santibáñez E, Palma M, Aravena E,
Barrientos C and Corvalan AH: Reprimo as a potential biomarker for
early detection in gastric cancer. Clin Cancer Res. 14:6264–6269.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Liu L and Yang X: Implication of Reprimo
and hMLH1 gene methylation in early diagnosis of gastric carcinoma.
Int J Clin Exp Pathol. 8:14977–14982. 2015.PubMed/NCBI
|
|
81
|
Lai J, Wang H, Luo Q, Huang S, Lin S,
Zheng Y and Chen Q: The relationship between DNA methylation and
Reprimo gene expression in gastric cancer cells. Oncotarget.
8:108610–108623. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Hu W, Zheng W, Liu Q, Chu H, Chen S, Kim
JJ, Wu J and Si J: Diagnostic accuracy of DNA methylation in
detection of gastric cancer: A meta-analysis. Oncotarget.
8:113142–113152. 2015. View Article : Google Scholar
|
|
83
|
Chen X, Lin Z, Xue M, Si J and Chen S:
Zic1 promoter hypermethylation in plasma DNA is a potential
biomarker for gastric cancer and intraepithelial neoplasia. PLoS
One. 10:e01339062015. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Xue WJ, Feng Y, Wang F, Li P, Liu YF, Guo
YB, Wang ZW and Mao QS: The value of serum RASSF10 hypermethylation
as a diagnostic and prognostic tool for gastric cancer. Tumour
Biol. 37:11249–11257. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Cheung KF, Lam CN, Wu K, Ng EK, Chong WW,
Cheng AS, To KF, Fan D, Sung JJ and Yu J: Characterization of the
gene structure, functional significance, and clinical application
of RNF180, a novel gene in gastric cancer. Cancer. 118:947–959.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Liu C, Li N, Lu H, Wang Z, Chen C, Wu L,
Liu J, Lu Y and Wang F: Circulating SFRP1 promoter methylation
status in gastric adenocarcinoma and esophageal square cell
carcinoma. Biomed Rep. 3:123–127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
epigenomics: Epigenomics AG gets CE-IVD
Mark for Lung Cancer Test Epi proLung(R). 2017.
|
|
88
|
Powrózek T, Krawczyk P, Kucharczyk T and
Milanowski J: Septin 9 promoter region methylation in free
circulating DNA-potential role in noninvasive diagnosis of lung
cancer: Preliminary report. Med Oncol. 31:9172014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Lee HS, Hwang SM, Kim TS, Kim DW, Park DJ,
Kang SB, Kim HH and Park KU: Circulating methylated septin 9
nucleic Acid in the plasma of patients with gastrointestinal cancer
in the stomach and colon. Transl Oncol. 6:290–296. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Lehmann-Werman R, Neiman D, Zemmour H,
Moss J, Magenheim J, Vaknin-Dembinsky A, Rubertsson S, Nellgård B,
Blennow K, Zetterberg H, et al: Identification of tissue-specific
cell death using methylation patterns of circulating DNA. Proc Natl
Acad Sci USA. 113:E1826–E1834. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Snyder MW, Kircher M, Hill AJ, Daza RM and
Shendure J: Cell-free DNA comprises an in vivo nucleosome footprint
that informs its tissues-of-origin. Cell. 164:57–68. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Kang S, Li Q, Chen Q, Zhou Y, Park S, Lee
G, Grimes B, Krysan K, Yu M, Wang W, et al: CancerLocator:
Non-invasive cancer diagnosis and tissue-of-origin prediction using
methylation profiles of cell-free DNA. Genome Biol. 18:532017.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Guo S, Diep D, Plongthongkum N, Fung HL
and Zhang K and Zhang K: Identification of methylation haplotype
blocks aids in deconvolution of heterogeneous tissue samples and
tumor tissue-of-origin mapping from plasma DNA. Nat Genet.
49:635–642. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Wan JCM, Massie C, Garcia-Corbacho J,
Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R and Rosenfeld N:
Liquid biopsies come of age: Towards implementation of circulating
tumour DNA. Nat Rev Cancer. 17:223–238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Heitzer E, Haque IS, Roberts CES and
Speicher MR: Current and future perspectives of liquid biopsies in
genomics-driven oncology. Nat Rev Genet. 20:71–88. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Leung F, Kulasingam V, Diamandis EP, Hoon
DS, Kinzler K, Pantel K and Alix-Panabières C: Circulating tumor
DNA as a cancer biomarker: Fact or fiction? Clin Chem.
62:1054–1060. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Bartels S, Persing S, Hasemeier B,
Schipper E, Kreipe H and Lehmann U: Molecular analysis of
circulating cell-free DNA from lung cancer patients in routine
laboratory practice: A cross-platform comparison of three different
molecular methods for mutation detection. J Mol Diagn. 19:722–732.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wan R, Wang Z, Lee JJ, Wang S, Li Q, Tang
F, Wang J, Sun Y, Bai H, Wang D, et al: Comprehensive analysis of
the discordance of EGFR mutation status between tumor tissues and
matched circulating tumor DNA in advanced non-small cell lung
cancer. J Thorac Oncol. 12:1376–1387. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Guttery DS, Page K, Hills A, Woodley L,
Marchese SD, Rghebi B, Hastings RK, Luo J, Pringle JH, Stebbing J,
et al: Noninvasive detection of activating estrogen receptor 1
(ESR1) mutations in estrogen receptor-positive metastatic breast
cancer. Clin Chem. 61:974–982. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Busser B, Lupo J, Sancey L, Mouret S,
Faure P, Plumas J, Chaperot L, Leccia MT, Coll JL, Hurbin A, et al:
Plasma circulating tumor DNA levels for the monitoring of melanoma
patients: Landscape of available technologies and clinical
applications. Biomed Res Int. 2017:59861292017. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Rachiglio AM, Esposito Abate R, Sacco A,
Pasquale R, Fenizia F, Lambiase M, Morabito A, Montanino A, Rocco
G, Romano C, et al: Limits and potential of targeted sequencing
analysis of liquid biopsy in patients with lung and colon
carcinoma. Oncotarget. 7:66595–66605. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Xu S, Lou F, Wu Y, Sun DQ, Zhang JB, Chen
W, Ye H, Liu JH, Wei S, Zhao MY, et al: Circulating tumor DNA
identified by targeted sequencing in advanced-stage non-small cell
lung cancer patients. Cancer Lett. 370:324–331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Newman AM, Lovejoy AF, Klass DM, Kurtz DM,
Chabon JJ, Scherer F, Stehr H, Liu CL, Bratman SV, Say C, et al:
Integrated digital error suppression for improved detection of
circulating tumor DNA. Nat Biotechnol. 34:547–555. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Phallen J, Sausen M, Adleff V, Leal A,
Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, et
al: Direct detection of early-stage cancers using circulating tumor
DNA. Sci Transl Med. 9:eaan24152017. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Belic J, Koch M, Ulz P, Auer M, Gerhalter
T, Mohan S, Fischereder K, Petru E, Bauernhofer T, Geigl JB, et al:
Rapid identification of plasma DNA samples with increased ctDNA
levels by a modified FAST-SeqS approach. Clin Chem. 61:838–849.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Kinde I, Wu J, Papadopoulos N, Kinzler KW
and Vogelstein B: Detection and quantification of rare mutations
with massively parallel sequencing. Proc Natl Acad Sci USA.
108:9530–9535. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Zhai J, Wu Y, Luo X, Li X and Yu DH:
Abstract 643: An ultra-sensitive multiplex allele-specific
real-time PCR (Udx-PCR) assay for detection of KRAS BRAF NRAS
mutations in colorectal cancer. Cancer Res. 78:6432018.
|
|
108
|
Chan KCA, Woo JKS, King A, Zee BCY, Lam
WKJ, Chan SL, Chu SWI, Mak C, Tse IOL, Leung SYM, et al: Analysis
of plasma epstein-barr virus DNA to screen for nasopharyngeal
cancer. N Engl J Med. 377:513–522. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Fiala C and Diamandis EP: Can Grail find
the trail to early cancer detection? Clin Chem Lab Med. 57:403–406.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Liu YH, Zhang LH, Ren H, Zhang GG, Qin F,
Kong GZ, Deng GR and Ji JF: Promoter hypermethylation of p16 gene
in pre- and post-operative plasma of patients with gastric
adenocarcinoma. Beijing Da Xue Xue Bao Yi Xue Ban. 37:257–260.
2005.(In Chinese). PubMed/NCBI
|
|
111
|
Koike H, Ichikawa D, Ikoma H, Otsuji E,
Kitamura K and Yamagishi H: Comparison of methylation-specific
polymerase chain reaction (MSP) with reverse
transcriptase-polymerase chain reaction (RT-PCR) in peripheral
blood of gastric cancer patients. J Surg Oncol. 87:182–186. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Guo X, Liu W, Pan Y, Ni P, Ji J, Guo L,
Zhang J, Wu J, Jiang J, Chen X, et al: Homeobox gene IRX1 is a
tumor suppressor gene in gastric carcinoma. Oncogene. 29:3908–3920.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zheng Y, Chen L, Li J, Yu B, Su L, Chen X,
Yu Y, Yan M, Liu B and Zhu Z: Hypermethylated DNA as potential
biomarkers for gastric cancer diagnosis. Clin Biochem.
44:1405–1411. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Ng EK, Leung CP, Shin VY, Wong CL, Ma ES,
Jin HC, Chu KM and Kwong A: Quantitative analysis and diagnostic
significance of methylated SLC19A3 DNA in the plasma of breast and
gastric cancer patients. PLoS One. 6:e222332011. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Chen L, Su L, Li J, Zheng Y, Yu B, Yu Y,
Yan M, Gu Q, Zhu Z and Liu B: Hypermethylated FAM5C and MYLK in
serum as diagnosis and pre-warning markers for gastric cancer. Dis
Markers. 32:195–202. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Raja UM, Gopal G and Rajkumar T:
Intragenic DNA methylation concomitant with repression of ATP4B and
ATP4A gene expression in gastric cancer is a potential serum
biomarker. Asian Pac J Cancer Prev. 13:5563–5568. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Ling ZQ, Lv P, Lu XX, Yu JL, Han J, Ying
LS, Zhu X, Zhu WY, Fang XH, Wang S and Wu YC: Circulating
methylated XAF1 DNA indicates poor prognosis for gastric cancer.
PLoS One. 8:e671952013. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Balgkouranidou I, Karayiannakis A,
Matthaios D, Bolanaki H, Tripsianis G, Tentes AA, Lianidou E,
Chatzaki E, Fiska A, Lambropoulou M, et al: Assessment of SOX17 DNA
methylation in cell free DNA from patients with operable gastric
cancer. Association with prognostic variables and survival. Clin
Chem Lab Med. 51:1505–1510. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Zhang H, Song Y, Xia P, Cheng Y, Guo Q,
Diao D, Wang W, Wu X, Liu D and Dang C: Detection of aberrant
hypermethylated spastic paraplegia-20 as a potential biomarker and
prognostic factor in gastric cancer. Med Oncol. 31:8302014.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Wang G, Zhang W, Zhou B, Jin C, Wang Z,
Yang Y, Wang Z, Chen Y and Feng X: The diagnosis value of promoter
methylation of UCHL1 in the serum for progression of gastric
cancer. Biomed Res Int. 2015:7410302015. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Li WH, Zhou ZJ, Huang TH, Guo K, Chen W,
Wang Y, Zhang H, Song YC and Chang DM: Detection of OSR2, VAV3, and
PPFIA3 methylation in the serum of patients with gastric cancer.
Dis Markers. 2016:57805382016. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Hu H, Chen X, Wang C, Jiang Y, Li J, Ying
X, Yang Y, Li B, Zhou C, Zhong J, et al: The role of TFPI2
hypermethylation in the detection of gastric and colorectal cancer.
Oncotarget. 8:84054–84065. 2017. View Article : Google Scholar : PubMed/NCBI
|
